Compare Cassava Sciences Inc (FLNA) vs Keysight Technologies Inc (KEYS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cassava Sciences Inc vs Keysight Technologies Inc — how do they compare? Cassava Sciences Inc trades at $1.1 (market cap $53.14M), while Keysight Technologies Inc trades at $322.57 (market cap $55.15B). The key difference: Keysight Technologies Inc is far larger — about 1037.8× Cassava Sciences Inc's market cap, and Keysight Technologies Inc is trading nearer its 52-week high, Cassava Sciences Inc nearer its low. Which is the better fit depends on your goals.
| FLNA | KEYS | |
|---|---|---|
Market Cap | $53.14M | $55.15B |
Sector | Health | Technology |
52-Week High | $4.64 | $373.34 |
52-Week Low | $1.09 | $158.51 |
Enterprise Value | -$33.43M | $55.50B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FLNA trades at $1.06, down 2.75% today, with a bearish technical signal from moving averages but neutral oscillators. The stock shows a low P/B of 0.78, yet profitability metrics are negative, including a -79.59% ROE and -$90.97M net income for 2025. Recent Q1 2026 earnings beat expectations, and analyst consensus is 66.7% buy. News highlights Q1 financial results and a scientific presentation on TSC-related epilepsy therapies.
Outlook remains speculative due to persistent losses and negative cash flows, offset by strong analyst support and recent earnings beats. Key risks include funding needs for drug development and competitive pressures, while potential upside hinges on clinical progress in TSC-related epilepsy treatments.
Keysight Technologies (KEYS) trades at $314.15, down 3.56% today, with a neutral technical outlook despite strong fundamental performance. The company has consistently beaten earnings estimates in recent quarters, with Q1 2026 EPS of $2.87 exceeding expectations by 24%. Recent developments include partnerships with the European Space Agency and new product launches in cybersecurity testing and photonics design automation, positioning the company for growth in 5G and AI-driven markets.
Wall Street maintains strong bullish sentiment with 81% buy ratings and a $396.56 consensus price target, representing 26% upside potential. However, elevated valuation ratios (P/E 51.97, P/S 9.14) and recent cash flow volatility present risks. The company's expansion into high-growth technology sectors provides opportunity, but investors should monitor execution on projected 2026 revenue growth to $6.1B.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →About Keysight Technologies Inc
Keysight Technologies is a leader in the field of testing and measurement, helping electronics OEMs and suppliers alike bring products to market to fit industry standards and specifications. Keysight specializes in the communications market, but also supplies into the government, automotive, industrial, and semiconductor manufacturing markets. Keysight's solutions include testing tools, analytical software, and services. The firm's stated objective is to reduce time to market and improve efficiency at its more than 30,000 customers.
Read more on KEYS →
